Global Medicare · Ovarian Research
ExoRegenOvo
Study 02-REGEN-AR
A prospective observational study comparing clinical and reproductive outcomes associated with two autologous PRP preparation approaches used within routine ovarian fertility care at IVF Baden-Baden.
Participation in the study is separate from clinical care. Treatment selection and final research eligibility belong to the authorised medical and research teams.
Study overview
ExoRegenOvo at a glance.
02-REGEN-AR is the ovarian observational study conducted at IVF Baden-Baden under the direction of Prof. Dr. med. Wolfgang Küpker.
Primary research question
Does the number of transferable embryos differ between patients receiving Standard-PRP and IAS within routine care?
The primary study objective is to compare the total number of transferable embryos obtained during a treatment sequence of up to three ovarian stimulation cycles.
The study does not assign Standard-PRP or IAS. The preparation is selected independently within clinical care.
Study design
Designed to observe routine clinical care, not assign it.
02-REGEN-AR documents ovarian and reproductive outcomes prospectively in patients already receiving one of two autologous preparation approaches within their clinical pathway.
Study information is documented forward in time.
Research observes routine care rather than assigning treatment.
The study is conducted at IVF Baden-Baden.
Standard-PRP and IAS are not assigned randomly by the study.
Study population
An ovarian-factor IVF / ICSI population.
The general study population consists of women aged 30 to 47 years with ovarian-factor concerns relevant to the protocol.
These are general study profiles, not an online eligibility checklist. The protocol includes additional clinical and laboratory criteria that must be reviewed by the authorised team.
Observation pathway
Up to three stimulation cycles may form part of the treatment sequence.
The actual number of cycles depends on the individual clinical course. Standard-PRP or IAS can be administered during the first and second retrievals; neither preparation is administered during the optional third retrieval.
Clinical stimulation, retrieval, IVF / ICSI laboratory outcomes and intraovarian Standard-PRP or IAS within routine care.
A second treatment cycle can be undertaken according to the individual clinical course, again with Standard-PRP or IAS.
If clinically required, a third cycle can be performed. No PRP or IAS is administered during the third retrieval.
The clinical pathway determines whether two or three cycles are performed; the research protocol does not require an unnecessary third cycle.
Study outcomes
The primary endpoint is accompanied by multiple secondary parameters.
IVF laboratory, ovarian, clinical and safety information can be documented within the observational framework.
Total number of transferable embryos obtained by the end of the treatment sequence.
Mature MII oocytes, embryo number, transferable embryos and embryo quality.
Ovarian parameters are documented as part of the broader clinical assessment.
Pregnancy, live birth and follow-up information can be documented where applicable.
These are study endpoints and data points. They are not a calculator of an individual patient’s probability of success.
Autologous preparations
Two preparation approaches. Selected clinically, observed scientifically.
Standard-PRP and IAS are autologous preparation approaches based on material from the patient’s own blood.
IAS includes additional processing of naturally occurring components from the same autologous blood sample.
The research study does not determine which preparation is used. Selection is made within routine clinical care according to the individual medical situation, availability and informed patient preference.
IAS should not be described as purified exosome therapy or presented as clinically superior to Standard-PRP.
Research governance
Conducted at IVF Baden-Baden.
The study is conducted under the direction of Prof. Dr. med. Wolfgang Küpker.
Important research information
Research participation should be understood separately from treatment.
Does this page confirm whether I am eligible for ExoRegenOvo?
Does the study decide whether I receive Standard-PRP or IAS?
Does participating guarantee that my ovarian response will improve?
Does research participation mean that treatment is free?
Can I join the study directly through this website?
Your next step
Interested in discussing your ovarian situation?
The Ovarian Program is the patient pathway for initial orientation, specialist evaluation and coordination with IVF Baden-Baden. Research participation, when applicable, is considered separately by the authorised team.